Payment overview · 2025
General Payments
$2,039.34
114 reported records · 18 companies
Healthcare provider profile · identity verified
Eman Kaldas, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AUGUSTA, GA · NPI 1336115187
Verified facts
What the public records show
CMS Open Payments records show Eman Kaldas, M.D. received $2,039.34 in general payments during 2025 across 114 reported records.
Novo Nordisk Inc accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $332.52 | 16.3% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $320.61 | 15.7% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $219.47 | 10.8% | 23 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $197.62 | 9.7% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $148.55 | 7.3% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $131.94 | 6.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.72 | 6.2% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $119.74 | 5.9% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $86.98 | 4.3% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.38 | 3.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.96 | 3.2% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $56.16 | 2.8% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $34.44 | 1.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.17 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.85 | 1.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.35 | 1.4% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.34 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.54 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,039.34 | 114 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $320.61 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $263.33 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $243.47 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $243.47 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $174.18 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $149.43 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $146.82 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $145.29 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $131.94 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $123.10 | 16 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $119.74 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $108.13 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $101.78 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.36 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $86.98 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $70.38 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.19 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $65.96 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $56.16 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.12 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.17 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.35 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.35 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.44 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.44 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.44 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $5.84 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $3.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $3.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 217 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 137 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 256 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 94 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 159 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
110 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
54 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
217 | 69 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
159 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
242 | 76 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
137 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
256 | 71 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
94 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1119 | 392 |
| Amlodipine Besylate | Amlodipine Besylate | 1081 | 395 |
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 157 |
| Gabapentin | Gabapentin | 496 | 180 |
| Losartan Potassium | Losartan Potassium | 495 | 173 |
| Pantoprazole Sodium | Pantoprazole Sodium | 455 | 165 |
| Tizanidine Hcl | Tizanidine Hcl | 442 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 405 | 144 |
| Lisinopril | Lisinopril | 392 | 132 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 387 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 350 | 121 |
| Tramadol Hcl | Tramadol Hcl | 340 | 120 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 327 | 125 |
| Carvedilol | Carvedilol | 314 | 109 |
| Clonazepam | Clonazepam | 314 | 89 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 311 | 112 |
| Meloxicam | Meloxicam | 304 | 105 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 296 | 102 |
| Zolpidem Tartrate | Zolpidem Tartrate | 282 | 72 |
| Furosemide | Furosemide | 262 | 89 |
| Ozempic | Semaglutide | 256 | 71 |
| Jardiance | Empagliflozin | 242 | 76 |
| Metformin Hcl | Metformin Hcl | 236 | 77 |
| Omeprazole | Omeprazole | 232 | 86 |
| Diazepam | Diazepam | 224 | 50 |
| Simvastatin | Simvastatin | 222 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 71 |
| Farxiga | Dapagliflozin Propanediol | 217 | 69 |
| Potassium Chloride | Potassium Chloride | 217 | 57 |
| Allopurinol | Allopurinol | 212 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 211 | 88 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 211 | 82 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 208 | 38 |
| Alprazolam | Alprazolam | 202 | 42 |
| Famotidine | Famotidine | 188 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 70 |
| Eliquis | Apixaban | 178 | 43 |
| Montelukast Sodium | Montelukast Sodium | 173 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 46 |
| Sertraline Hcl | Sertraline Hcl | 164 | 62 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 159 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 156 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 144 | 55 |
| Donepezil Hcl | Donepezil Hcl | 143 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 50 |
| Mounjaro | Tirzepatide | 137 | 33 |
| Pregabalin | Pregabalin | 130 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 46 |
| Metformin Hcl Er | Metformin Hcl | 116 | 35 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 113 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 110 | 33 |
| Linzess | Linaclotide | 110 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 41 |
| Bupropion Xl | Bupropion Hcl | 104 | 28 |
| Spironolactone | Spironolactone | 100 | 31 |
| Trazodone Hcl | Trazodone Hcl | 99 | 35 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 96 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 39 |
| Rybelsus | Semaglutide | 94 | 36 |
| Glipizide | Glipizide | 92 | 29 |
| Lorazepam | Lorazepam | 91 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | 30 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 85 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 75 | 23 |
| Ibuprofen | Ibuprofen | 75 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 21 |
| Celecoxib | Celecoxib | 69 | 15 |
| Meclizine Hcl | Meclizine Hcl | 67 | 32 |
| Tresiba Flextouch U-200 | Insulin Degludec | 65 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 63 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 62 | 20 |
| Atenolol | Atenolol | 61 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 23 |
| Levetiracetam | Levetiracetam | 60 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 17 |
| Trintellix | Vortioxetine Hydrobromide | 58 | 12 |
| Lovastatin | Lovastatin | 57 | 16 |
| Ezetimibe | Ezetimibe | 55 | 17 |
| Myrbetriq | Mirabegron | 54 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 24 |
| Clonidine | Clonidine | 52 | 21 |
| Colchicine | Colchicine | 52 | 25 |
| Topiramate | Topiramate | 52 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 21 |
| Carisoprodol | Carisoprodol | 49 | suppressed |
| Azithromycin | Azithromycin | 48 | 46 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | suppressed |
| Belsomra | Suvorexant | 47 | 24 |
| Clonidine Hcl | Clonidine Hcl | 46 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 14 |
| Methimazole | Methimazole | 46 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 13 |
| Methocarbamol | Methocarbamol | 45 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 11 |
| Januvia | Sitagliptin Phosphate | 44 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 13 |
| Irbesartan | Irbesartan | 41 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Glimepiride | Glimepiride | 40 | 14 |
| Megestrol Acetate | Megestrol Acetate | 40 | 13 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 15 |
| Nifedipine Er | Nifedipine | 39 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 14 |
| Valsartan | Valsartan | 38 | 14 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | 13 |
| Finasteride | Finasteride | 35 | 11 |
| Prednisone | Prednisone | 34 | 30 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 14 |
| Chlorthalidone | Chlorthalidone | 33 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | 11 |
| Ketoconazole | Ketoconazole | 29 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Lidocaine | Lidocaine | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | 11 |
| Bumetanide | Bumetanide | 27 | 12 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 22 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | 11 |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,039.34 · 114 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error